Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125898221 | 12589822 | 1 | I | 20111018 | 20160714 | 20160725 | 20160725 | EXP | JP-CELGENEUS-JPN-2016073884 | CELGENE | 74.00 | YR | M | Y | 0.00000 | 20160725 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125898221 | 12589822 | 1 | PS | VIDAZA | AZACITIDINE | 1 | Intravenous drip | U | U | 50794 | 130 | MG | INJECTION | ||||||
| 125898221 | 12589822 | 2 | SS | VIDAZA | AZACITIDINE | 1 | Intravenous drip | U | U | 50794 | 130 | MG | INJECTION | ||||||
| 125898221 | 12589822 | 3 | SS | VIDAZA | AZACITIDINE | 1 | Intravenous drip | U | U | 50794 | 130 | MG | INJECTION | ||||||
| 125898221 | 12589822 | 4 | SS | VIDAZA | AZACITIDINE | 1 | Intravenous drip | U | U | 50794 | 130 | MG | INJECTION | ||||||
| 125898221 | 12589822 | 5 | SS | VIDAZA | AZACITIDINE | 1 | Intravenous drip | U | U | 50794 | 130 | MG | INJECTION | ||||||
| 125898221 | 12589822 | 6 | SS | VIDAZA | AZACITIDINE | 1 | Intravenous drip | U | U | 50794 | 130 | MG | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125898221 | 12589822 | 1 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125898221 | 12589822 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125898221 | 12589822 | Abdominal discomfort | |
| 125898221 | 12589822 | Abdominal distension | |
| 125898221 | 12589822 | Bradycardia | |
| 125898221 | 12589822 | C-reactive protein increased | |
| 125898221 | 12589822 | Constipation | |
| 125898221 | 12589822 | Diarrhoea | |
| 125898221 | 12589822 | Dry throat | |
| 125898221 | 12589822 | Haemorrhage subcutaneous | |
| 125898221 | 12589822 | Injection site erythema | |
| 125898221 | 12589822 | Injection site induration | |
| 125898221 | 12589822 | Injection site pain | |
| 125898221 | 12589822 | Musculoskeletal stiffness | |
| 125898221 | 12589822 | Nausea | |
| 125898221 | 12589822 | Nephrogenic anaemia | |
| 125898221 | 12589822 | Renal impairment | |
| 125898221 | 12589822 | Serum ferritin increased | |
| 125898221 | 12589822 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125898221 | 12589822 | 1 | 20111018 | 20111024 | 0 | |
| 125898221 | 12589822 | 2 | 20111116 | 20111124 | 0 | |
| 125898221 | 12589822 | 3 | 20111214 | 20111221 | 0 | |
| 125898221 | 12589822 | 4 | 20120202 | 20120209 | 0 | |
| 125898221 | 12589822 | 5 | 20120308 | 20120315 | 0 | |
| 125898221 | 12589822 | 6 | 20120507 | 20120519 | 0 |